Pfizer, Moderna vaccines are 90% effective after two doses in study of real-life conditions, CDC confirms (Washington Post)

Washington Post: Pfizer, Moderna vaccines are 90% effective after two doses in study of real-life conditions, CDC confirms. “In a study of about 4,000 health-care personnel, police, firefighters and other essential workers, the Centers for Disease Control and Prevention found that the vaccines reduced the risk of infection by 80 percent after one shot. Protection increased to 90 percent following the second dose. The findings are consistent with clinical trial results and studies showing strong effectiveness in Israel and the United Kingdom, and in initial studies of health-care workers at the UT Southwestern Medical Center and in Southern California.”

University of North Carolina at Chapel Hill: Single vaccine dose may offer protection to those who have had COVID-19

University of North Carolina at Chapel Hill: Single vaccine dose may offer protection to those who have had COVID-19. “New research from the University of North Carolina at Chapel Hill suggests that people who have had COVID-19 may need only one shot of vaccine. The study led by the UNC School of Medicine and Gillings School of Global Public Health showed one dose of either the Pfizer-BioNTech or Moderna vaccine – known as mRNA vaccines – boosted antibodies among those who previously had COVID-19.”

Mashable: Why all 3 U.S. vaccines are excellent options

Mashable: Why all 3 U.S. vaccines are excellent options. “All the FDA-authorized vaccines (there are currently three) are outstanding options, according to infectious disease experts. Why? ‘All of them look great at preventing disease that results in hospitalization and death,’ emphasized Dr. Thomas Russo, the chief of infectious disease at the University of Buffalo’s Jacobs School of Medicine and Biomedical Sciences. Here’s what to know.”

Washington Post: Moderna agreed to ‘equitable access’ for its coronavirus vaccine, but most of its doses are going to wealthy countries

Washington Post: Moderna agreed to ‘equitable access’ for its coronavirus vaccine, but most of its doses are going to wealthy countries. “Moderna ‘seems to have refused to allocate or sell any of their supply beyond the wealthiest countries, the most profitable markets,’ said Suerie Moon, co-director of the Global Health Center at the Graduate Institute of International and Development Studies in Geneva.”

Moderna: Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa

Moderna: Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa. “Moderna Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced results from in vitro neutralization studies of sera from individuals vaccinated with Moderna COVID-19 Vaccine showing activity against emerging strains of SARS-CoV-2. Vaccination with the Moderna COVID-19 Vaccine produced neutralizing titers against all key emerging variants tested, including B.1.1.7 and B.1.351, first identified in the UK and Republic of South Africa, respectively.”

Covid: Moderna vaccine moves closer to US approval (BBC)

BBC: Covid: Moderna vaccine moves closer to US approval. “A second coronavirus vaccine is nearing emergency approval in the US after it was endorsed by a panel of experts. The head of the Food and Drug Administration (FDA) said his agency would move quickly to authorise the Moderna vaccine, allowing the company to begin shipping millions of doses.”

BBC: Moderna vaccine safe and effective, say US experts

BBC: Moderna vaccine safe and effective, say US experts. “Moderna’s vaccine is safe and 94% effective, regulators say, clearing the way for US emergency authorisation. The analysis by the Food and Drug Administration’s (FDA) means it could become the second coronavirus vaccine to be allowed in the US. It comes one day after Americans across the country began receiving jabs of the Pfizer-BioNTech vaccine.”

Exclusive: Moderna vaccine trial contractors fail to enroll enough minorities, prompting slowdown (Reuters)

Reuters: Exclusive: Moderna vaccine trial contractors fail to enroll enough minorities, prompting slowdown. “Private contractors hired by Moderna Inc to recruit volunteers for its coronavirus vaccine trial failed to enroll enough Black, Latino and Native American participants to determine how well the vaccine works in these populations, company executives and vaccine researchers told Reuters.”

CBS News: Moderna CEO says its coronavirus vaccine won’t be ready until spring of next year

CBS News: Moderna CEO says its coronavirus vaccine won’t be ready until spring of next year. “Moderna CEO Stéphane Bancel said Wednesday that his company’s coronavirus vaccine won’t be ready for widespread public distribution until spring of next year, according to a report. The drugmaker also won’t seek emergency authorization for the vaccine for frontline medical workers and other at-risk individuals until November 25 at the earliest, he told the Financial Times.”

CNN: Moderna coronavirus vaccine shows ‘promising’ safety and immune response results in published Phase 1 study, but more research is needed

CNN: Moderna coronavirus vaccine shows ‘promising’ safety and immune response results in published Phase 1 study, but more research is needed. “A Covid-19 vaccine developed by the biotechnology company Moderna in partnership with the National Institutes of Health has been found to induce immune responses in all of the volunteers who received it in a Phase 1 study.”

National Geographic: A COVID-19 vaccine has passed its first human trial. But is it the frontrunner?

National Geographic: A COVID-19 vaccine has passed its first human trial. But is it the frontrunner?. “A PROMISING CORONAVIRUS vaccine candidate cleared a key hurdle this week, when Moderna Therapeutics entered phase two of clinical trials. The move signals that the company’s mRNA vaccine has passed its initial safety checks and has met an important milestone in bringing this drug closer to the public and commercial markets.”

New York Times: How Upbeat Vaccine News Fueled a Stock Surge, and an Uproar

New York Times: How Upbeat Vaccine News Fueled a Stock Surge, and an Uproar. “Moderna’s stock price jumped as much as 30 percent. Its announcement helped lift the stock market and was widely reported by news organizations, including The New York Times. Nine hours after its initial news release — and after the markets closed — the company announced a stock offering with the aim of raising more than $1 billion to help bankroll vaccine development. That offering had not been mentioned in Moderna’s briefings of investors and journalists that morning, and the company chairman later said it was decided on only that afternoon.”